Regeneron Pharmaceuticals, Inc. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (60)

Latest Posts

About This Stock More About This Stock
Family-Owned Firms: Trading At A Discount
Article By: ValueWalk
Saturday, October 7, 2017 9:39 PM EST
Ffor each of the past ten years, family-owned companies have shown stronger revenue growth than their non-family-owned peers. Also, R&D spending has been higher, balance sheets strong and margins wider.
In this article: CCW, LVMHF, REGN, CMCSA, ORCL, FB, FOX
Read
Regeneron/Sanofi's Dupixent Asthma Study Meets Endpoints
Article By: Zacks Investment Research
Monday, September 11, 2017 4:50 PM EST
Regeneron Pharmaceuticals, Inc. and partner Sanofi announced that Dupixent (dupilumab) met its two primary endpoints in a phase III study conducted on patients with uncontrolled, persistent asthma.
In this article: SNY, REGN Also: ALXN, ADRO
Read
5 Top-Ranked Biotech Stocks To Buy Right Now
Article By: Arpita Dutt
Monday, September 11, 2017 1:09 PM EST
Picking biotech stocks can be a bit tricky given the “high risk - high returns” nature of the industry. Moreover, the estimate revision trend for the sector is not very encouraging.
In this article: REGN, ALXN, LGND, SGMO, FATE Also: KITE, GILD
Read
How To Protect Your Money After A Tough Earnings Season
Article By: Sam Subramanian
Sunday, August 27, 2017 7:27 PM EST
The second quarter earnings reporting season has proved to be a difficult one for stocks. The earnings reports themselves have been strong. Yet, second quarter earnings reports have been unable to lift stock prices.
In this article: HAL, HAS, REGN, NTAP
Read
4 Biotech Stocks To Add To Your Portfolio Post Q2 Earnings
Article By: Arpita Dutt
Tuesday, August 22, 2017 12:02 PM EST
The second half of 2017 is expected to be catalyst rich for quite a few companies with data expected across a wide range of therapeutics areas.
In this article: ALXN, GILD, REGN, LGND Also: AMGN, NVS
Read

PARTNER HEADLINES

Latest Tweets for $REGN

No tweets yet!